{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:42:24Z","timestamp":1702730544856},"reference-count":51,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fexofenadine hydrochloride (HCl) is a second\u2010generation, nonsedating, histamine H1\u2010receptor antagonist used to manage seasonal allergic rhinitis and chronic idiopathic urticaria. A new oral pediatric suspension of fexofenadine HCl has been developed, with the preservative potassium sorbate replacing parabens. The objective of this phase 1 single\u2010center, open\u2010label, randomized, 2\u2010treatment, full\u2010replicated, 4\u2010period, 2\u2010sequence crossover study in healthy adult volunteers was to assess the bioequivalence of 30\u00a0mg of the new oral suspension of fexofenadine HCl (test) versus 30\u00a0mg of the marketed pediatric oral suspension of fexofenadine HCl (reference). The replicate design was based on the high intra\u2010individual variability of fexofenadine (&gt;30% on C<jats:sub>max<\/jats:sub>). The study comprised 68 randomized and treated volunteers. Plasma concentrations of fexofenadine were similar following the administration of a single dose of each formulation. C<jats:sub>max<\/jats:sub>, AUC<jats:sub>last<\/jats:sub>, AUC, median t<jats:sub>max<\/jats:sub>, and mean t<jats:sub>1\/2z<\/jats:sub> were similar between administrations of the same fexofenadine formulation and between formulations. A high intra\u2010individual variability was confirmed with both formulations. Bioequivalence of the test and reference fexofenadine HCl formulations was demonstrated as the 90% confidence intervals of the geometric least squares mean ratio for C<jats:sub>max<\/jats:sub>, AUC<jats:sub>last<\/jats:sub>, and AUC of fexofenadine were all within the bioequivalence range of 0.80\u20101.25. There were no serious adverse events (AEs) or study discontinuations due to treatment\u2010emergent AEs with either fexofenadine HCl formulation. The new paraben\u2010free fexofenadine HCl 30\u2010mg oral suspension and marketed fexofenadine HCl 30\u2010mg pediatric oral suspension are bioequivalent under fasting conditions, with no safety concerns and a safety profile consistent with the known profile of fexofenadine.<\/jats:p>","DOI":"10.1002\/cpdd.1311","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:57:11Z","timestamp":1693555031000},"page":"1194-1203","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension"],"prefix":"10.1002","volume":"12","author":[{"given":"Clemence","family":"Rauch","sequence":"first","affiliation":[{"name":"Clinical Development &amp; Biometry Sanofi CHC Gentilly France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz","family":"Lucio","sequence":"additional","affiliation":[{"name":"Allergy, Sanofi CHC S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice Bois","family":"De Fer","sequence":"additional","affiliation":[{"name":"Clinical Development &amp; Biometry Sanofi CHC Gentilly France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Lheritier\u2010Barrand","sequence":"additional","affiliation":[{"name":"Science Innovation, Sanofi CHC Gentilly France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22073_c"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3796"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100533"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00365-3"},{"issue":"3","key":"e_1_2_9_6_1","first-page":"1","article-title":"Chronic urticaria: following practice guidelines","volume":"23","author":"Westby EP","year":"2018","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059020-00020"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63041-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70070-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321896"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00806-2020"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0363-1"},{"issue":"2","key":"e_1_2_9_13_1","first-page":"414","article-title":"Efficacy of fexofenadine in the treatment of chronic idiopathic urticaria","volume":"29","author":"Jahan H","year":"2020","journal-title":"Mymensingh Med J"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61325-7"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2004.00167.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/9884960-000000000-00000"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60385-7"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60553-4"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62317-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1384"},{"issue":"4","key":"e_1_2_9_21_1","first-page":"169","article-title":"The efficacy and safety of 30\u00a0mg fexofenadine HCl bid in pediatric patients with allergic rhinitis","volume":"23","author":"Ngamphaiboon J","year":"2005","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.12.032"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfv074"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218224"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/wics.1310"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-019-09623-w"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00592-y"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1459565"},{"key":"e_1_2_9_29_1","first-page":"19","article-title":"Fexofenadine hydrochloride in the treatment of allergic disease: a review","volume":"1","author":"Axelrod D","year":"2008","journal-title":"J Asthma Allergy"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90052-2"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.688"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2008.29.3136"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.2.329"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199810)19:7<455::AID-BDD130>3.0.CO;2-W"},{"key":"e_1_2_9_35_1","first-page":"S390","article-title":"Mass balance and pharmacokinetics of MDL 16455A in healthy male volunteers","volume":"12","author":"Lippert C","year":"1995","journal-title":"Pharm. Res."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.10000198"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00867-1"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009342251"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.08.043"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.689"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.425"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12955"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.1060218"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6753"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S280330"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105162"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tifs.2018.07.012"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.4172\/pharmaceutical-sciences.1000164"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-014-9356-2"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80192-8"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0631-z"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.069"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:15:44Z","timestamp":1702728944000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cpdd.1311"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1311","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2023-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}